Cambridge, MA and Shenzhen, China – March 7, 2022 – XtalPi, a pioneering artificial intelligence (AI) drug research and development (R&D) company today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
XtalPi is a quantum physics and AI-powered pharmaceutical technology company. Its one-stop AI drug discovery service combines cloud-based prediction models and high-throughput wet-lab experiments as two mutually informative and validating arms of a closed iterative feedback loop. Together with its team of experienced pharmaceutical scientists, such in-house capabilities allow XtalPi to quickly and reliably discover and optimize promising drug candidates with well-rounded property profiles that are more likely to succeed in the subsequent steps of clinical studies. XtalPi is empowering pharmaceutical innovation with drug discovery services for small molecules and biologics, as well as drug solid-state R&D services for small molecule pre-clinical development.
In 2021, XtalPi has grew its business by several folds despite the challenge of the pandemic. The company moved into a new headquarter in Shenzhen and opened an innovation center in Shanghai, gaining more than 100,000 square feet of lab space for targeted drug synthesis, solid-state research, biological studies, and cryo-EM experiments. Such expansion has added to XtalPi’s growing capabilities in generating high-quality research data, iterating prediction models, and delivering optimal pipeline candidates with proven drug properties.
As a US-China-based, global-minded pharma tech company, XtalPi is serving over 100 clients with a team of 600 employees around the world. In addition to growing its team, XtalPi has incubated and invested in innovative startup companies of complementary skill sets and strategic symbiosis to XtalPi’s platform, gradually building an ecosystem of fast-rising startups like METiS Pharmaceuticals, Signet Therapeutics, PhoreMost, and Leman Biotech.
“It’s an honored to be recognized by the Fierce 15 list,” says Jian Ma, co-founder, and CEO of XtalPi. “As an AI industry platform, we will continue to integrate quantum physics and AI algorithms with wet-lab technology and expert domain knowledge to empower a wide range of innovative pharmaceutical research, and help our clients bring more breakthrough treatments to patients worldwide with less time and resources needed.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Medtech’s 10th annual Fierce 15 selection. This year’s full list of winners can be viewed online at https://www.fiercebiotech.com/special-reports/fierce-medtechs-2021-fierce-15
“While we’re not fully out of the woods yet when it comes to COVID-19, the innovations pursued by this year’s class of 15 companies will help the industry evolve, either in step with the pandemic or in spite of it,” said Conor Hale, senior editor of Fierce Medtech.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day’s top stories.
We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty, and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators.
We operate an integrated technology platform that combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities.